CompletedPhase 4ACTRN12606000132549

Randomised crossover trial of a porous haemodialysis membrane compared to a conventional high-flux membrane in stable haemodialysis patients to determine the short term impact on inflammatory and nutritional indices.

Sponsor

Fresenius

Enrollment

30 participants

Start Date

Jun 30, 2006

Study Type

Interventional

Conditions

Haemodialysis

Summary

This trial examines whether a new dialysis membrane has potential advantages to the patients by way of determining whether the membrane results in less of an inflammatory state - reflected by both markers of inflammation and nutrition in the blood. It is a short term pilot study only, as a possible lead in to a longer more detailed study. The dialysis membranes will be supplied blinded in that all will look the same (but carry a code) such that the treating dialysis nurses and the patients will be unaware of which dialyser is in use at any given time.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 80 Yearss

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying: Randomised crossover trial of a porous haemodialysis membrane compared to a conventional high-flux membrane in stable haemodialysis patients to determine the short term impact on inflammatory and nutritional indices.. It may be open to adults aged 18 to 80 who meet certain criteria, including: Stable haemodialysis patients, currently dialysed with FX60 dialysers. Participation typically involves medical assessments, possible treatment with the study intervention, and follow-up visits to track your health.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

30 stable haemodialysis patients will be randomly assigned to either continue on conventional high-flux dialysis with the FX60 membrane or the new modified-FX membrane. Equal numbers in each group.

30 stable haemodialysis patients will be randomly assigned to either continue on conventional high-flux dialysis with the FX60 membrane or the new modified-FX membrane. Equal numbers in each group. Cross-over after 6 weeks. Total study duration 12 weeks.